Last week, we honored our Veterans. Now, we’re listening to what they shared about the challenges of accessing #NMIBC care.
A new ImmunityBio survey conducted by @HarrisPoll found that 63% of veterans with NMIBC have faced treatment barriers, including long appointment waits (35%) and difficulty coordinating VA and non-VA care (27%).
These statistics represent delays and uncertainty for people who've already given so much. Researching and working to expand treatment options for patients with NMIBC is part of how we're working to change that.
Explore the full survey results: https://t.co/XDnEbFukuy
ImmunityBio ranked No. 2 on the 2026 @Deloitte Technology Fast 500™, reflecting revenue growth of more than 47,000% from 2022 to 2025.
Thank you to our employees and partners for their contributions to this milestone.
Read the full announcement: https://t.co/yzx8BOHDX3
$IBRX #fast500
At #SNO2026, Dr. Simon Khagi presented QUILT-3.078 in a rapid oral session, exploring the investigational combination of ANKTIVA® (N-803) + PD-L1 t-haNK cell therapy in recurrent glioblastoma.
Together, we’re advancing neuro-oncology research.
#Glioblastoma#NeuroOncology
To our Veterans: Thank you for your service.
As we honor you today, we recognize the impact of bladder cancer on the Veteran community. According to a new ImmunityBio survey conducted by @HarrisPoll, 53% of Veterans and military service members with NMIBC were diagnosed by age 50, including 28% by age 40.
Throughout November, we’ll be sharing what Veterans told us about navigating NMIBC to bring greater awareness to their experiences and needs.
Learn more about what Veterans shared: https://t.co/XDnEbFukuy
ImmunityBio shared three announcements today:
· QUILT-2.005: ANKTIVA® plus BCG met the primary endpoint in Cohort A of the randomized BCG-naïve, high-grade NMIBC trial
· Israel Approval: ANKTIVA® plus BCG was approved for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors
· Q3 2026 & Global Progress: Net product revenue reached $48.7 million, up 53% year over year, alongside U.S. label expansion and an additional global approval
Read the full releases for complete information and important disclosures:
https://t.co/4nGOGxDECL
Each November, #LungCancerAwarenessMonth highlights the importance of education, early detection, and innovation.
ImmunityBio is proud to support this awareness by researching new approaches for patients with lung cancer, where significant unmet need remains.
ImmunityBio is heading to #LUGPA2026.
We look forward to learning, connecting, and celebrating the strength of independent urology with practice leaders and clinicians.
Visit us at booth #712 to connect with our team.
We're thrilled to share a major milestone: the first patients in Europe have been treated with ANKTIVA® + BCG for BCG-unresponsive NMIBC with CIS, beginning in Germany & Austria, following the EC's February 2026 conditional authorization.
With support from partners Accord Healthcare and Uniphar, we're working to expand access for eligible patients across Europe.
Full press release & Important Safety Information: https://t.co/3AB9PPdjwh
ImmunityBio Medical Affairs leadership will be attending #SITC26, taking place November 4-8 in Phoenix.
We're excited to connect with colleagues across the oncology community and take part in conversations advancing cancer immunotherapy.
If you're attending, we hope to see you there.
We were honored to join the oncology community at #ESMO26 in Madrid, sharing progress in our mission to harness the power of immunotherapy.
The energy and collaboration throughout the week reinforced what drives us: advancing innovative treatments with the goal of improving outcomes and quality of life for patients worldwide.
Thank you to our team and collaborators who make this work possible.
Progress in research happens one study at a time.
We're committed to transparency in our clinical development programs. Stay informed about where our investigational candidates stand.
Check our latest pipeline updates: https://t.co/jzMALyOFKN
We've completed the database lock for our QUILT-2.005 trial evaluating ANKTIVA® plus BCG as a potential first locally delivered, chemotherapy-free combination for BCG-naïve bladder cancer.
Topline results are expected in November 2026, with supplemental Biologics License Application submission on track for Q4 2026.
Learn more: https://t.co/9TYTKyXHcB
ImmunityBio is excited to attend the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid - a highly influential global oncology meeting bringing together clinicians, researchers, patient advocates, and industry leaders from around the world.
#ESMO26 will be a platform for advances in oncology research, clinical practice, and patient care.
We look forward to engaging with the global oncology community, exploring impactful new data, and contributing to the future of cancer care on a global scale. @myESMO
New Phase 3 data published in the @JUrology highlights long‑term durability findings from our QUILT‑3.032 study evaluating ANKTIVA® plus BCG in patients with BCG‑unresponsive #NMIBC, with 84% cystectomy‑free survival at three years and complete responses extending beyond 53 months.
Read the full press release: https://t.co/ySR9uHGoQG
We are pleased to announce that the U.S. Food and Drug Administration (@FDA) has expanded the indication for ANKTIVA® (nogapendekin alfa inbakicept‑pmln) + BCG to include patients with BCG‑unresponsive non‑muscle‑invasive bladder cancer (NMIBC) with papillary‑only tumors.
This milestone makes ANKTIVA + BCG the first FDA‑approved therapy for both CIS and papillary‑only disease in the BCG‑unresponsive NMIBC setting. Because papillary tumors represent approximately 85 % of NMIBC diagnoses, this approval significantly broadens access to a bladder‑sparing option for patients who face high risk of recurrence and progression.
Read more: https://t.co/prIgphlGKf
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval.
https://t.co/azWUTpNxjm
We're hiring at our new Dunkirk facility.
ImmunityBio is expanding our manufacturing operations and seeking talented professionals in Manufacturing & Operations, QA/QC, Process Engineering, and Regulatory Affairs. Join us in our mission to develop innovative immunotherapies that transform patient outcomes.
Apply now: https://t.co/oviRry3BsP
@DrPatrick will join @Piper_Sandler Virtual Oncology Symposium on Oct 16, 1PM ET for a fireside chat on ImmunityBio’s clinical progress and vision for cancer immunotherapy.
https://t.co/VwckKZkojR
Contact Piper Sandler for information about attending the symposium and accessing session recordings.
@DrPatrick will join @Piper_Sandler Virtual Oncology Symposium on Oct 16, 1PM ET for a fireside chat on ImmunityBio’s clinical progress and vision for cancer immunotherapy.
https://t.co/VwckKZkojR
Contact Piper Sandler for information about attending the symposium and accessing session recordings.